Home > Insider Trading > Filing (0001415889-24-008681)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1623526	Stoke Therapeutics Inc.	STOK	Pharmaceutical Preparations (2834)	471144582

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1966716	Jonathan Allan	C/O Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford MA 01730	General Counsel & Corp Sec	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-03-15	7,475	$0.00	10,073	No	4	M	Direct
Common Stock	Disposition	2024-03-19	2,349	$6.10	7,724	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-03-15	7,475	$0.00	7,475	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,425		2027-03-15	No	4	M	Direct

Footnotes

The reported total includes an aggregate 2,598 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.